June 14, 2007
India's Biotech Exports Reach
$1.2 bn in 2006-07
New Delhi
Revenues from India's biotech industry exports grew by 47 percent to
reach $1.2 billion in the financial year ending March 2007,
according to a survey.
The leading pharma companies, which contributed almost 27 percent of
the industry revenue, are Serum Institute, Biocon and Panacea Biotec,
according to the survey conducted by BioSpectrum, a journal
published by the CyberMedia Group, along with Association of
Biotechnology Led Enterprises (ABLE).
The industry introduced more than a dozen new products along with
several new transgenic cottonseeds for the bio-agri sector.
According to the survey, as much as 400 firms would earn revenues of
about $5 billion by 2010, bringing almost 100 biotech products in
the market.
The biopharma segment, accounting for over two-thirds of the
industry, reported sales of Rs.59.73 billion, representing a growth
of 27 percent. The bioservices sector registered 53 percent growth,
the bioagri sector 55 percent, and the bioinformatics and
bioindustrial sectors recorded growth of 21 percent and 5 percent
respectively.
Last year witnessed numerous mergers and acquisitions in this sector
with Pune-based Serum Institute picking up a 14 percent stake in
Britain-based Lipoxen focussing on developing biologicals, vaccines
and oncology drugs.
Biocon's Syngene tied up with Bristol-Myers Squibb to provide
research and development services for discovery and early drug
development.
Boloji.com is owned and managed by Boloji Media Inc Privacy Policy |
Disclaimer
No part of this Internet site may
be reproduced without prior written permission of the copyright holder.